Quester-backed biopharmaceutical company Oxxon Therapeutics has been acquired by London Stock Exchange-listed Oxford BioMedica Plc for £16m. The sale to Oxford BioMedica, a company previously backed by Prelude Trust before being floated, represents a partial exit for Quester and co-investors Isis College Fund, NIF Ventures, Gray Ghost, NVM and Neomed Innovation ASA. The acquisition of Oxxon provides Oxford BioMedica with a cancer immunotherapy product candidatre to complement its own such candidate and adds to its gene-based medicine portfolio.
GP also announced the refinancing of online gardening retailer YouGardem, scoring a 60% cost return
CDP Venture and Tim Ventures take part in the round, alongside Club Digital and Club Italia Investimenti 2
Deal is the second from Bid Equity II, which held a close in November 2019 and targets B2B software
Early-stage investor Italian Angels for Growth and Swiss holding company Brahma also take part in the round